Drug name (maker) Indication Revenue for 2005 1 Eprex/Procrit (Ortho Biotech) Anemia $3,324M 2 Aranesp (Amgen) Anemia $3,273M 3 Enbrel (Amgen) Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis $2,573M 4 Remicade (J&J) Crohn's disease, ankylosing spondylitis, arthritis, ulcerative colitis $2,535M 5 Epogen (Amgen) Anemia $2,455M 6 Herceptin (Genentech) Breast cancer $2,416M 7 Neulasta (Amgen) Infection associated with chemotherapy

Company Product Marketer (at time of approval) Indication (U.S. Approval Date, Month/Year) 1982 Genentech Inc. Humulin Eli Lilly and Co. Diabetes (10/82) 1985 Genentech Inc. Protropin Genentech Inc. Growth hormone inadequacy; growth failure associated with chronic renal insufficiency in children (10/85) 1986 Biogen Inc.* Intron-A Schering-Plough Corp. Hairy cell leukemia (6/86); genital warts (6/88); AIDS-related Kaposi's sarcoma (11/88); hepatitis C (2/91); hepatitis B (7/92

Amgen Inc. 12,800 Genentech Inc. 7,500 Chiron Corp. 5,332 Serono International SA 4,900 Biogen Idec Inc. 4,000 Cephalon Inc. 2,300 MedImmune Inc. 2,000 Ortho Biotech Products LP 2,000 Gilead Sciences Inc. 1,800 Sepracor Inc. 1,750 Celgene Corp. 1,000 Serologicals Corp. 1,000 ImClone Systems Inc. 861 Human Genome Sciences Inc. 850 Promega Corp. 758 Nabi Biopharmaceuticals Inc. 700 Celltech Group plc 650 Martek Biosciences Corp. 636 Cangene Corp. 600 Myriad

(in millions of dollars) Public offerings Private biotechs Public/other Total Jan. 585.7 406.3 744.9 1,736.9 Feb. 799.4 636.6 701.1 2,137.1 March 303.9 276.4 717.0 1,297.3 April 71.2 182.4 309.2 562.7 May 143.3 611.1 202.6 957.0 June 599.6 439.7 1,796.7 2,835.6 July 390.9 262.4 2,393.9 3,047.2 Aug. 730.5 435.4 764.7 1,930.6 Sept. 491.0 361.6 570.9 1,423.4 Oct. 527.8 588.8 266.3 1,382.8 Nov. 562.7 293.7 503.4 1,359.7 Dec. 373.8 314.9

Money Raised By Biotech, 2000-2005 (in billions of U.S. dollars) Public/Other Private Biotechs Public Offerings 2000 10.09 3.94 23.64 2001 6.12 3.75 4.49 2002 5.33 3.23 1.39 2003 9.46 3.33 3.63 2004 10.46 4.89 5.46 2005 9.73 4.81 5.58 SOURCE: BioWorld Financial Watch

Global Pharmaceutical and Biotech Industry Sales and Projection*, 2003-2008 (in billions of U.S. dollars) Year 2003 2004 2005 2006* 2007* 2008* Pharmaceutical 467.1 523.6 592.7 658.4 697.9 748.7 Biotechnology 41.7 49.9 58.1 64.0 70.9 80.1 SOURCE: BioWorld

The success of the biotechnology industry to-date and in the near future is directly tied to its ability to sustain its own innovation, its relationship with pharma and, to a lesser degree, survive the impact of a biogenerics policy. Innovation is a market indicator that has defined and carried the biotechnology market since its inception. Its founding principle of biological discovery is the reason we differentiate it from the pharmaceutical industry. Before there were biologics drugs

Proper name: Bevacizumab Type: Anticancer Developer: Genentech Inc. Location: South San Francisco, California Web address: www.gene.com Indication(s): For treatment of people diagnosed with metastatic colorectal cancer for the first time, and receiving intravenous 5-fluorouracil (5-FU)-based chemotherapy Approval Date: February 2004 2005 Revenue: $1.13 billion Patients are more likely to survive if cancer cells do not. Avastin is making progress in realizing that long-sought-after

Proper name: Lamivudine + Zidovudine Type: Anti-HIV Drug Developer: GlaxoSmithKline plc Location: Brentford, United Kingdom Website: www.gsk.com Indication(s): For the treatment of HIV-1 Approval Date: September 1997 2005 Revenue: $1.06 billion Given its apocalyptic potential, HIV is a disease for which something has to be done. It, just as the avian bird flu does, can supercede the funding limits and safety responsibilities of corporate investors and executives, in commanding the

Proper name: Interferon beta-1b Type: Autoimmune drug Drug Developer: Chiron Corp. Location: Emeryville, California Website: www.chiron.com Indication(s): For the treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations Approval Date: August 1993 2005 Revenue: $1.05 billion Like Avonex (interferon beta-1a), Betaseron is widely used for the treatment of multiple sclerosis. Both are classified as type I cytokines, which are known for their

1. Lipitor (atorvastatin) 2005 Revenue: $12.187 billion First approved December 17, 1996, Pfizer Inc.'s Lipitor is indicated for the reduction of low-density lipoprotein cholesterol. It is the most widely used treatment for lowering cholesterol-an important indication in the United States, where one in three people have high cholesterol. According to Pfizer's 10-Q report from October 2005, Lipitor has a 40% market share among lipid-lowering prescriptions. The drug has been prescribed to more

Proper name: Glatiramer acetate injection Type: Autoimmune drug Drug Developer: Teva Nueroscience Inc. Location: Kansas City, Missouri Website: www.tevaneuroscience.com Indication(s): For the reduction of relapses in relapsing-remitting multiple sclerosis Approval Date: December 1996 2005 Revenue: $1.18 billion Copaxone is the first and only non-interferon multiple sclerosis (MS) drug on the market and its presence on the list is an example of biotechnology and pharma merging on a

Proper name: Insulin Lispro Type: Insulin diabetes therapeutic Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For quick-response mealtime management of hyperglycemia in patients with diabetes mellitus Approval Date: June 1996 2005 Revenue: $1.20 billion Humalog is in the class of fast-acting insulins that give users greater flexibility and better control in the monitoring and application of their self-treatment therapeutic plans

Proper name: Adalimumab Type: Anti-inflammatory agent Developer: Abbott Laboratories Location: Abbott Park, Illinois Web address: www.abbott.com Indication(s): For the treatment of rheumatoid arthritis or psoriatic arthritis Approval Date: December 2002 2005 Revenue: $1.4 billion Humira is approved for reducing the symptoms, inducing major clinical response, slowing the progression of joint damage, and improving physical function in adult patients with moderate-to-severe rheumatoid

Proper name: Human insulin (rDNA origin) Type: Insulin diabetes therapeutic Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For replacement action of natural insulin in the management of hyperglycemia in patients with diabetes mellitus Approval Date: January 1994 2005 Revenue: $1.005 billion Humulin, Eli Lilly and Co.'s long-acting book-end drug for Humalog, it's quick-acting complement, is built for stability rather than speed, in

Proper name: Insulin Glargine (rDNA origin) Type: long-acting insulin diabetes therapeutic Developer: Genentech Inc. Location: South San Francisco, California Web address: www.gene.com Indication(s): Adults with Type 2 diabetes or adults and children (6 years and older) with Type 1 diabetes who require long-acting insulin for the control of high blood sugar Approval Date: April 2000 2005 Revenue: $1.48 billion Lantus is an insulin therapy and its claim to fame is that it was the first

Proper name: Peginterferon alfa-2a Type: Anti-viral Drug Developer: F. Hoffmann-La Roche Ltd. Location: Basel, Switzerland Website: www.roche.com Indication(s): For the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease, and for the treatment of adults with hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation. Approval Date: October 2002 2005 Revenue: $1.09 billion The most long-lasting blood

Proper name: Filgrastim Type: Anticancer, anti-infective Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): For the treatment of chemotherapy-induced neutropenia, for bone marrow transplant accompanied by neutropenia, bone marrow transplant engraftment or failure, mobilization of autologous peripheral blood progenitor cells (PBPCs) after chemotherapy and severe chronic neutropenia Approval Date: February 1991 2005 Revenue: $1.22 billion